Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing impactful medicines for patients and families with neurological disorders in the United States. The company's primary revenue stream comes from the development and potential commercialization of drug candidates such as OV101, OV329, OV350, OV882, and OV815, which are targeted at treating fragile X syndrome, seizures associated with tuberous sclerosis complex and infantile spasms, epilepsies, angelman syndrome, and kinesin-family of proteins associated neurological disorder, respectively.

Products

• OV101 - Drug candidate for fragile X syndrome

• OV329 - GABA aminotransferase inhibitor for seizures associated with tuberous sclerosis complex and infantile spasms

• OV350 - Small molecule for treating epilepsies

• OV882 - Short hairpin RNA gene therapy for angelman syndrome

• OV815 - Treatment for kinesin-family of proteins associated neurological disorder